Icosavax Reports Positive 12-Month Durability Data for VLP Vaccine Candidate IVX-121 Against RSV and Initial Evidence for Revaccination Potential
August 08, 2023 16:05 ET
|
Icosavax, Inc.
- In new data from Icosavax’s IVX-121 Phase 1b extension trial in older adults, GMTs against RSV through day 365 persisted at ~45-70% of the GMTs at day 28 (for 75 and 250 µg unadjuvanted dosages) - ...
Icosavax Initiates Phase 2 Trial of IVX-A12 Against RSV and hMPV in Older Adults
June 20, 2023 08:00 ET
|
Icosavax, Inc.
- Phase 2 topline interim results expected in 1Q 2024 - - 6-month durability data for Phase 1 trial of IVX-A12 also expected in 1Q 2024 - SEATTLE, June 20, 2023 (GLOBE NEWSWIRE) --...
Icosavax Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 10, 2023 16:05 ET
|
Icosavax, Inc.
- IVX-A12 (RSV+hMPV) Phase 1 topline interim data expected in 2Q 2023 - - Initiation of IVX-A12 Phase 2 trial expected in 2H 2023 - - Cash and cash equivalents, restricted cash, and short-term...